Background

Fluoxetine hydrochloride is one of the familiar antidepressants of the second generation and has the effect of inhibiting the reuptake of 5-hydroxytryptamine by central nervous system. Both clinical trials and animal experiments show that it has good antidepressant effect, but there are few reports on its clinical efficacy in treating depression patients from the perspective of metabolomics. This study aimed at evaluating the antidepressant effect of fluoxetine hydrochloride by metabolomics, so that to find out its specific biomarkers and related metabolic characteristics of depression in the treatment of depression and analyze the intervention mechanism of fluoxetine hydrochloride in depression.

Method

Twenty depression patients and twenty healthy volunteers were recruited in clinical. Using ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) to analyze serum metabolites of depression patients pretherapy and post-treatment and compared with healthy people.

Result

Finally, we have detected 16 specific biomarkers of depression. Compared with the healthy group, the level of 10 biomarkers in the depression group was significantly increased (P < 0.05) and 6 biomarkers were significantly decreased (P < 0.01). After 8 weeks of fluoxetine hydrochloride treatment, all the biomarkers have showed a tendency of callback. The metabolic pathways involved include amino acid metabolism, energy metabolism and lipid metabolism.

Conclusion

In our study, the antidepressant effect of fluoxetine hydrochloride in clinic was proved by metabolomics and provided basis for clinical use of fluoxetine hydrochloride. At the same time, the biomarkers that may be related to the occurrence of depression are determined to provide objective basis for the diagnosis of depression.

中文翻译：

---

盐酸氟西汀治疗抑郁症的临床血清代谢组学研究

背景

盐酸氟西汀是第二代中常见的抗抑郁药之一，具有抑制5-羟色胺被中枢神经系统再摄取的作用。临床试验和动物实验均显示其具有良好的抗抑郁作用，但从代谢组学的角度来看，有关其治疗抑郁症患者临床疗效的报道很少。本研究旨在通过代谢组学评估盐酸氟西汀的抗抑郁作用，从而找出其在抑郁症治疗中的特定生物标志物和相关的代谢特征，并分析盐酸氟西汀对抑郁症的干预机制。

方法

临床招募了20名抑郁症患者和20名健康志愿者。使用超高效液相色谱四极杆飞行时间质谱（UPLC-Q-TOF / MS）分析抑郁症患者治疗前和治疗后的血清代谢产物，并与健康人进行比较。

结果

最后，我们检测到了16种抑郁症的特定生物标记。与健康组相比，抑郁症组中10种生物标志物的水平显着升高（P  <0.05），而6种生物标志物的水平显着降低（P  <0.01）。盐酸氟西汀治疗8周后，所有生物标志物均显示出回调的趋势。涉及的代谢途径包括氨基酸代谢，能量代谢和脂质代谢。

结论

在我们的研究中，盐酸氟西汀的抗抑郁作用在代谢组学中得到了证明，为盐酸氟西汀的临床应用提供了依据。同时，确定可能与抑郁症发生有关的生物标志物，为诊断抑郁症提供客观依据。